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Abstract
Background & Purpose: Opioid maintenance therapy (OMT) is an effective method of treating
opioid addiction. Of incarcerated individuals in the U.S., 50-85% have a history of substance
abuse, and >80% of inmates with opioid addiction history do not receive treatment. The purpose
of this study was to explore individuals’ experiences after being tapered from OMT upon
incarceration. Methods: Interpretative phenomenological analysis (IPA) was employed using indepth interviewing of 10 participants. Results: Analysis identified six themes that captured the
essence of the participants’ experiences. Implications & Conclusion: Losing OMT upon
incarceration was described as an extremely stressful experience for many individuals, and may
create issues for both inmates and facility staff. Further research is needed to discover ways in
which to improve addiction treatment in prison.
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Introduction
Substance related offenses are responsible for at least half of federal prison sentences.
Between 50-85% of incarcerated individuals in the U.S. have a history of substance abuse, with
20% of those reporting intravenous (IV) drug use (Nunn 2009). Between 9-13% of incarcerated
individuals in 2004 reported using heroin on a regular basis pre-incarceration (Mumola &
Karberg, 2006), and between 12%-25% of newly arrested individuals tested positive for opioids
upon urinalysis (National Institute of Justice, 2004). The availability of illicit substances in
prisons has been well documented (United Nations Office on Drugs and Crime, 2010), and
needle-sharing behaviors in prison settings greatly increase risk for HIV and hepatitis C
acquisition during incarceration (United Nations Office on Drugs and Crime, 2010). Opioid
maintenance treatment (OMT) with either methadone or buprenorphine is an effective method of
decreasing opioid abuse and promoting increased health in community and prison settings. It has
also been found to decrease individual involvement with the criminal justice system and
HIV/hepatitis C infection (Gordon, Kinlock, Schwartz, O’Grady, 2008) as well as increase
quality of life in the community-dwelling population (Nosyk et al., 2012). While detoxification
programs are also utilized for treatment of opioid dependence, they have been found to be less
effective than OMT at reducing illicit behaviors, substance use, and needle sharing (Nosyk et al.,
2012). The World Health Organization has called for OMT to play a major role in substance
abuse programs, including those in prison settings (2013), and the National Institute on Drug
Abuse (NIDA) includes OMT in its principle for addiction treatment of both the general and
inmate population (2012).
Opioid maintenance treatment in the prison setting has been found to result in a decrease
in opioid use as well as decreased drug injecting and needle sharing (NIDA, 2012). While
inmates frequently report accessibility to illicit substances and means to inject drugs in prison,
only 55% of U.S. state and federal prisons provide methadone or buprenorphine, and more than
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half of those prisons only do so for pregnant women or to treat chronic pain rather than addiction
(Nunn 2009). More than 80% of inmates with known addiction histories do not receive treatment
while incarcerated (Chandler, Fletcher & Volkow, 2009). Many incarcerated individuals with a
history of opioid abuse have been enrolled in an OMT program prior to incarceration (Fiscella,
Moore, Engerman, Meldrum, 2004), but rates of initiation into OMT after release from prison are
low, and the risk of overdose is elevated in the period immediately following reintegration back
into the community (World Health Organization, 2013). Hendrich et al. (2011) found that six
months following release from prison, more than 50% of individuals who were able to receive
OMT in prison continued treatment in the community, while only five percent of individuals who
did not receive OMT while incarcerated enrolled in a community-based OMT program upon
release from prison. Individuals with a history of pre-incarceration heroin addiction typically
relapse within one month of release from prison if they are not enrolled in an OMT program
(Gordon, Kinlock, Schwartz, O’Grady, 2008). Reasons for relapse can include anxiety and
depression related to “stigma associated with being labeled an ex-offender, the need for housing
and legitimate employment, stresses in reunifying with family, and multiple requirements for
criminal justice supervision,” (p. 184) as well as reintegration into a community where substances
are highly available and accessible (Chandler, Fletcher, & Volkow, 2009).
Rates of successful long term, voluntary tapers from OMT in medically supervised
community-based treatment centers are generally considered poor. Nosyk et al.’s (2012)
population-based, retrospective cohort study found that only 13% of community-dwelling
individuals who attempted a medically supervised, voluntary taper from OMT were considered
successful, meaning they avoided relapse and/or reentry into OMT. Calsyn, Malcy, & Saxon
(2006) reported a zero percent success rate following a voluntary, medically supervised
methadone taper. However, because the accessibility of OMT in prison settings is poor, many
individuals who are enrolled in an OMT program are involuntarily tapered from methadone or
2

buprenorphine upon incarceration at a rate that is much faster than what is generally considered
appropriate within a community-based OMT setting (Fiscella, Moore, Engerman, Meldrum,
2004).
Purpose
Given the stress associated with incarceration, it is important to explore the experiences
of individuals who have undergone involuntary discontinuation or taper while serving time in
prison. The purpose of this study was to discover, explore, and describe these experiences.
Implicit within the goal is to discover the essence of their experience during this time and learn
about what the experience was like for them.
Research Question
The overarching research question was: “what are the experiences of individuals who are
tapered from OMT upon incarceration?” Secondary aims explored how being tapered from OMT
affected the participants’ lives following release and reintegration back into the community.
Significance
Little is known about the experiences of individuals who were tapered from OMT when
incarcerated. This study provided information about the experiences of individuals tapered off of
OMT, which is lacking in the current literature. The study findings may help guide further
research in this area, which will help inform future policies about the delivery of addiction care in
prison settings. This is particularly important considering the percentage of incarcerated
individuals who report past or present substance abuse and addiction.
Advanced Practice Registered Nurse (APRN) Competencies
This study integrated the APRN competencies related to scientific foundations, quality of
care, health policy, and health care delivery. The purpose of this study was to generate data about
the experiences of individuals, the analysis of which inform health policy and improve the quality
of nursing and healthcare for the incarcerated and drug-using populations. In these ways, this
3

study integrated all four of the previously stated competencies. A nurse researcher is the principal
investigator and will collaborate with other nurses, medical providers, and counselors at a
community OMT clinic to successfully complete the proposed study, thereby fulfilling the APRN
leadership competencies.
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Comprehensive Literature Review
This review of the literature will begin by providing background information about
opioid maintenance treatment. It will then examine the current research relating to the effect of
OMT on quality of life and overdose risk of community dwelling populations. It will conclude by
reviewing research of OMT’s use and effect in prison settings.
Opioid Maintenance Treatment
Opioid maintenance treatment (also known as replacement or substitution therapy) refers
to the use of either methadone or buprenorphine to treat opioid addiction. Methadone is a full
opioid agonist and buprenorphine is a partial opioid agonist, and both medications function by
binding to opiate receptors and reducing drug withdrawal symptoms and drug cravings (Whelan
and Remski, 2012). Correct doses of methadone and buprenorphine (which vary between
patients) can also inhibit the effects of other opioids so that the “high” that is desired when an
individual uses another opioid is not achieved. The primary goals of treatment are to help
individuals addicted to opioids refrain from using illicit substances and abusing opioid
prescription pain medication, decrease withdrawal symptoms, and aid in addiction recovery
(Centers for Disease Control, 2002). Treatment with methadone or buprenorphine does not come
without risks, as either of the medications can cause dose-dependent intoxication or fatality. Both
medications also have abuse potential and are therefore subject to diversion and street dealing.
(Whelan and Remski, 2012). In a randomized study comparing buprenorphine (16-32mg), low
dose methadone (20mg), and high dose methadone (60-100mg), buprenorphine and high dose
methadone were found to be equally more effective at reducing opioid abuse than low dose
methadone, without significant differences in reported side effects (Johnson, Chutuape, Strain,
Walsh, Stitzer & Bigelow, 2000).
Opioid maintenance therapy is most often administered at outpatient substance abuse
clinics and inpatient treatment centers, and its effectiveness is increased when it is paired with
5

other treatment modalities such as counseling and group meetings such as 12-step programs
(NIDA, 2012). Buprenorphine is a newer medication in the treatment of opioid addiction and has
not been as widely utilized as methadone. It is administered at substance abuse treatment centers
as well as in primary care settings by independent providers with special licensing. When utilized
for substance abuse treatment purposes (as opposed to pain management), methadone must be
administered through a federally certified substance abuse clinic (Substance Abuse and Mental
Health Services Administration, 2013). The choice of medication to treat opioid addiction is
related to numerous factors including level of opioid dependence, prescriber preference, and
medication availability (Whelan and Remski, 2012). There are currently no clear, universal
guidelines to help prescribing clinicians decide whether methadone or buprenorphine is
appropriate for their patients. Some clinicians utilize their patients’ drug-use histories to
determine if buprenorphine will be effective, as individuals with heavier illicit opioid use might
be better maintained on methadone as it can be successfully titrated to higher doses than
buprenorphine (V. Esparza, personal interview, April 1, 2014). Buprenorphine is also more
expensive in the United States than is methadone, which may affect prescribing in some
situations (V. Esparza, personal interview, April 1, 2014).
The administration of OMT requires careful upward titration to ensure that patients
receive a dose that eliminates withdrawal symptoms without causing intoxication, and the optimal
dosage differs from patient to patient. Both medications also cause withdrawal symptoms when
discontinued abruptly and slow tapering is advised to decrease the severity of withdrawal
symptoms. Withdrawal symptoms can be extremely uncomfortable and include diarrhea, nausea,
vomiting, body aches, sweating, chills, tremors, irritability, intense opioid cravings, and anxiety;
these symptoms are reportedly so unbearable that stopping or even decreasing use is extremely
difficult for most individuals to tolerate without some form of treatment (Harvard Medical
School, 2004). Neurobiological changes in the brain from chronic drug exposure may
6

significantly limit impulse control in individuals suffering from opioid addiction, which can
provide an extra challenge for individuals attempting to stop using substances (Chandler,
Fletcher, Volkow, 2009). Opioid withdrawal is generally not life threatening, but it can cause
miscarriage in pregnant individuals (Harvard Medical School, 2004).
Quality of Life and Opioid Maintenance Therapy
While there is a lack of information about the ways in which opioid maintenance
treatment impacts the quality of life of prisoners, OMT has been found to have a positive effect
on quality of life ratings of individuals in community settings. Baharom, Hassan, Ali and Shah
(2012) conducted a retrospective chart review to compare quality of life for 122 men with
histories of opioid addiction before beginning OMT to quality of life after six months of OMT at
a Malaysian community clinic. The World Health Organization Quality of Life survey was
administered at baseline and after six months in treatment and these scores were compared for
changes in four categories: physical, psychological, relationships, and living
situation/environment. The researchers found that six months of OMT was associated with
significantly higher scores in all four categories, with the psychological category showing the
most significant improvement.
A qualitative study conducted by De Maeyer et al. (2011) in Belgium utilizing in-depth
interviews uncovered five recurrent themes that were associated with quality of life for
individuals who had been enrolled in a community-based OMT program for 5-10 years. These
themes were social relationships, psychological well-being, employment, independence, and
leading a meaningful life. Each of these categories were reported to be either negatively or
positively affected by methadone treatment. While participants reported that methadone increased
their quality of life by allowing them to handle responsibilities and function better in relationships
with others, they also reported that being enrolled in a methadone program caused them to
experience discrimination, which negatively affected their relationships. A positive impact on
7

quality of life within the occupation theme was related to the ability to gain employment while
maintained on methadone, but a reported negative impact with regards to limited job
opportunities and lack of perceived high-quality jobs was also noted. This study highlights the
complexity of issues surrounding quality of life and OMT treatment. While participants reported
several negative impacts that OMT has had on their lives, many of these are perhaps due to
stigma associated with OMT (discrimination with regards to employment or relationships) rather
than OMT itself. This study is limited by a lack of a pre-OMT comparison group, so it is
unknown whether the participants would have reported significantly lower scores before
treatment.
Korthuis et al. (2011) compared self-reported health-related quality of life scores of 289
HIV-positive individuals with opioid addiction before beginning treatment with buprenorphine to
scores after 12 months of treatment with buprenorphine OMT at a community-based clinic.
Utilizing the Medical Outcomes Study Short Form Health Survey (SF-12), the researchers found
that quality of life was significantly improved (β 1.13; 95% CI 0.72, 1.54) after 12 months of
treatment, specifically in the mental health, vitality, social functioning, and emotional functioning
categories. Individuals with previous 30-day incarceration were found to have lower mental
health quality of life ratings. The significance of this is unclear and may be related to the
individuals having HIV and a history of incarceration.
Ponizovsky et al. (2010) conducted a similar pre-post, 32-week longitudinal study of 105
HIV-negative individuals receiving buprenorphine over the time span of 32 weeks. Several
different scales were utilized to assess quality of life, including the Quality of Life Enjoyment and
Satisfaction Questionnaire, General Self-Efficacy Scale, and the Multidimensional Scale of
Perceived Social Support. After 32 weeks in treatment, there was a significant improvement
(p<.001) in quality of life, enjoyment and satisfaction, general self-efficacy, and perceived social
support. Importantly, these effects were achieved at 16 weeks and sustained over 32 weeks.
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Although not specific to incarcerated individuals, these finding suggest that OMT positively
affects quality of life.
Although there are no studies comparing quality of life between individuals receiving
methadone and buprenorphine, studies suggest that enrollment in either type of OMT has a
positive impact on quality of life. Improved quality of life may provide motivation for individuals
to avoid illicit substance use and activities, and may motivate them to make positive changes in
their lives. While little is known about how OMT affects the quality of life of incarcerated
individuals, the continuation of OMT upon incarceration may help individuals adjust to the prison
setting and allow them to participate in daily activities such as work duty and classes without
withdrawal symptoms. Participation in educational programs while in prison has been found to
be associated with decreased rates of recidivism upon release (Davis, Bozick, Steele, Saunders,
Miles, 2013). Individuals may be unable to fully participate in educational programs during the
weeks-to-months long withdrawal phase, which and may affect present and future quality of life
as well as recidivism rates.
Decrease in Risk of Overdose & Community-based Opioid Maintenance Treatment
Overdose is the most common cause of death among injection drug users, outnumbering
deaths due to infectious disease (e.g. HIV, hepatitis C, tuberculosis) and non-infectious causes
(e.g. cancers, heart disease, liver disease) (World Health Organization, 2013). Cases of non-fatal
overdose can cause significant morbidity related to cerebral hypoxia, including permanent brain
damage (World Health Organization 2013). The World Health Organization reports that OMT is
responsible for a significant decrease in the risk of opioid overdose (2013). Gronbladh, Ohlund,
and Gunne (1990) conducted a seminal study that compared the mortality outcomes of a group of
individuals addicted to heroin receiving methadone treatment (n=166) vs. a group of of individual
addicted to heroin who were not receiving methadone treatment (n=115) over 8 years. The rate of
deaths related to overdose in the group not receiving methadone treatment was found to be
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significantly higher than in the group maintained on methadone (x2= 20.29, P<0.0001), and none
of the individuals in the group receiving methadone died from overdose due to heroin. Causes of
mortality in the group receiving methadone included overdose due to substances other than
heroin, endocarditis, and liver disease. Mortality rates for individuals maintained on methadone
were 1.4% per year, compared to 7.2% for the untreated controls and 6.9% per year for those
involuntarily discharged from the methadone program.
Similarly, Langendam, van Brussel, Coutinho, and van Ameijden (2001) utilized a
prospective cohort model to study the rates of mortality from opioid overdose in drug users who
were maintained on methadone compared to drug users who were not maintained on methadone.
Eight hundred and twenty seven participants from the Amsterdam Cohort Study were included in
the study. The researchers found that injection drug users who were not maintained on methadone
were more than four times more likely to die due to overdose than injection drug users who were
maintained, regardless of methadone dosage. More recently, a longitudinal time series analysis
was conducted by Schwartz et al. (2013) that studied overdose deaths in Baltimore, Maryland
between the years of 1995-2009. The researchers found that an increase in OMT availability
throughout the city was associated with a decrease in annual deaths by opioid overdose by 37%.
While this study found that OMT was associated with a decrease in opioid overdose, it was
limited in that it only included overdoses from heroin and morphine, rather than overdoses caused
by opioid prescription pain medication (oxydocone, hydrocodone, etc.).
Methadone and buprenorphine are also associated with overdose. Utilized for pain
control (2% of prescriptions in 2009) as well as addiction treatment, methadone was implicated in
at least 30% of deaths involving prescription pain medication during the year 2009 (Kuehn,
2012). However, while increased methadone prescribing for pain control has been associated with
increases in methadone overdoses, higher rates of supervised methadone administration has been
associated with lower rates of methadone associated overdose (Strang, Hall, Hickman, & Bird,
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2010). Although the research is limited in this area, this suggests that the lethality associated with
methadone and methadone overdose may be related to the clinical indications for use. For
example, individuals receiving methadone for opioid dependence generally take methadone at
lower dosing frequency and are maintained in a controlled environment (Substance Abuse and
Mental Health Services Administration, 2013). Buprenorphine has been speculated to be safer
than methadone due to the fact that it is a partial rather than full opioid agonist, which may partly
account for its approval for administration in primary care and other less regulated settings
(Auriacombe, Fraques, Tignol, 2001). However, buprenorphine can still cause overdose, and
OMT clinics that prescribe it must be careful to carefully titrate doses and carefully monitor for
signs of diversion.
Incarcerated Populations and Opioid Maintenance Treatment
The vast majority of incarcerated individuals with a history of opioid abuse do not have
access to OMT (WHO, 2013). When individuals who are patients at a community-based OMT
program in some states are incarcerated and their stay is estimated to be longer than 30 days, they
are often tapered from their methadone or buprenorphine dose unless they are pregnant (Correct
Care Solutions 2011; McKenzie et al. 2009; Fu et al., 2012). Cropsey et al. (2012) conducted a
study in which the researchers mailed surveys regarding health care access to US prison
administrators. Four hundred and thirty one facilities with a total of 7,843,785 inmates responded
to the survey. It was reported that methadone was provided at 17.4% of these facilities, and 3.6%
of inmates received treatment. Buprenorphine OMT program availability was not studied.
Chandler, Fletcher and Volkow report that less that 1% of incarcerated individuals in the US have
access to OMT (2009). Reasons for the discontinuation of OMT upon incarceration and the
unavailability of OMT in prisons are not fully transparent, although they may have to do with
concerns of diversion, logistical difficulties, and the belief that illicit substances are difficult to
obtain in correctional facilities, as well as general stigma about opioid addiction (McKenzie et al.,
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2009). Addiction medicine is a specialty and Chandler, Fletcher, and Volkow (2009) speculate
that few prison providers have received adequate training to provide effective substance abuse
treatment. Lack of understanding about the neuropathology of addiction can also lead to the
stigmatization of substance users, which can cause decreased motivation on the part of both
prison-based health care providers and policy makers to guarantee comprehensive treatment for
all incarcerated individuals (Chandler, Fletcher, Volkow, 2009).
As mentioned previously, many different factors can contribute to the decision regarding
whether to administer methadone or buprenorphine OMT to a patient. The administration of
buprenorphine may take longer than that of methadone in a prison setting, with buprenorphine
preparation and administration taking about 15 minutes and methadone preparation taking 1-3
minutes in one study (Magura, 2009). It may be that health resources cannot accommodate the
associated time burden of buprenorphine administration. Buprenorphine may also be easier to
divert, as it is administered in a dissolving tablet or film form, while liquid methadone must be
swallowed immediately. As diversion of medication is a serious concern in the prison setting, it
may be another reason why prisons are hesitant to provide OMT, with either methadone or
buprenorphine (Magura, 2009).
Mental Illness & Stressors in the Prison Population
Incarceration can represent a major life change for many individuals and can cause stress
related to separation from loved ones, fiscal worries (especially if the incarcerated individual had
been financially supporting others), change in daily routine, and social difficulties with other
inmates. For inmates who had been maintained on OMT prior to incarceration, tapering from
OMT may be yet another cause of increased stress and come with significantly uncomfortable
withdrawal symptoms. In addition, research suggests that prisoners report high numbers of past
traumatic life events that can cause symptoms of post-traumatic stress disorder. Maschi, Gibson,
Zgoba, and Morgen (2011) interviewed a random sample of 58 adult male inmates about history
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of trauma, including abuse, witnessing violence, kidnapping, illness, and loss of a loved one.
Forty-three percent reported being physically abused as a child, 89% reported witnessing
violence, 61% reported seeing someone shoot another person, 29% reported experiencing a life
threatening illness, and 88% reported the death of a loved one. Abram et al. (2007) found that
more that 90% of incarcerated youth (n=898) interviewed reported history of a major traumatic
event, with 11% reporting symptoms congruent with PTSD within the past year. In comparison,
only 4-9% of non-incarcerated youth report these symptoms.
Cauffman et al. (1998) found that 65% of incarcerated female adolescents reported PTSD
symptoms (n=96), which the researchers state is 6 times higher than the general population. In
addition, 41-65% of those struggling with substance abuse also have or would meet criteria for
co-morbid mental health disorders, including anxiety disorders and PTSD (U.S Department of
Health and Human Services, 1999). Binswanger et al. (2010) found that 44% of incarcerated
women and 22% of incarcerated men who responded to the US Survey of Inmates at Local Jails
reported having a mental health diagnosis other than substance abuse disorders, including
depression, anxiety, bipolar disorder, PTSD, and psychosis. Although self reported, these findings
suggest high levels of PTSD or general stress within the inmate population that might make
adjustment to a substantial life change (incarceration) difficult, especially when coupled with a
second significant stressor such as tapering from OMT. In addition, untreated mental illness in the
prison setting can lead to issues such as inmate violence (including sexual violence) (Dumond,
2003) and suicide attempts (Chavez, 2012). Increased stress related to untreated addiction may
intensify these risks.
Retention in Opioid Maintenance Treatment, Relapse, and Recidivism
Gordon, Kinlock, Schwartz, and O’Grady (2008) conducted a randomized clinical trial
that compared the effectiveness of three different types of interventions in male inmates (n=201)
with a history of heroin addiction. Subjects were randomly allocated to receive either counseling
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only, counseling with referral to OMT (specifically methadone) programs, and counseling with
initiation of methadone treatment three to six months before release from prison. The counseling
with initiation of methadone group began treatment with methadone a few weeks before their
release dates and were then transferred to an outpatient treatment center for continuation of care
once they were released from prison. At six months post release, 65% of counseling only
participants, 48% of the counseling with referral participants, and 28% of the counseling with
initiation of OMT participants tested positive for illicit opioids. The participants in the counseling
with initiation of OMT group attended a treatment program for a significantly greater number of
days than those in the two other groups, with the counseling only group having the lowest number
of days. The individuals in the counseling only group also reported a significantly higher number
of days in which they participated in criminal activity compared to the referral (p<0.0001) and
initiation groups (p<0.002) (56.6 days vs. 35.6 and 28.5, respectively) (Gordon, Kinlock,
Schwartz, and O’Grady 2008). These results suggest that OMT, when initiated prior to release
from prison, may help previously incarcerated individuals avoid relapse and activities that could
cause re-arrest.
Kinlock, Gordon, Schwartz, Fitzgerald, and O’Grady (2009) conducted a 12-month
follow up study post-incarceration to examine opioid relapse and recidivism. Follow up data was
available for 97% of initial participants. Participants who had received counseling with OMT
reported an average of 166 days in a community based clinic, those who had received counseling
with referral reported an average of 91.3, and those who had received only counseling reported an
average of 23.1 (Kinlock et al., 2009). This suggests that the initiation of opioid maintenance
treatment with counseling in prison is associated with greater long-term involvement in
community-based treatment programs after release from prison than counseling with referral or
counseling alone. Recidivism was not significantly related to intervention group in either study,
but neither of the studies thoroughly analyzed the reasons for reincarceration. Kinlock et al.
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(2009) suggest that arrests may have been related to probation violations and earlier offenses
rather than substance abuse.
McMillan, Lapham and Lackey (2008) conducted a retrospective chart review to study
the recidivism history of 589 inmates at a prison in the Southwest US with an OMT program.
The program allowed inmates who had been patients at a methadone clinic prior to incarceration
to continue to receive methadone while incarcerated. They compared time from release to
reincarceration of inmates who had received OMT during incarceration versus inmates who did
not receive OMT while incarcerated. A primary reason for an inmate not receiving OMT
involved difficulty verifying dosage history with the community-based methadone clinic. No
significant difference in time between release from prison to recidivism and reincarceration was
seen between the two groups. However, this study did not take into consideration whether
inmates were able to continue OMT at a community clinic after release. It also did not examine
any differences that may have existed between inmates who were receiving OMT in prison and
those who were not receiving OMT besides length of time incarcerated. Length of time
incarcerated can affect ability to receive OMT because verification of dosage with the outside
clinic can be a lengthy process and individuals with longer sentences may be more likely to have
their dosage verified. This study also failed to explore reasons for re-incarceration, which may
have included issues related to probation from previous offenses and crimes that were not drug
related.
Larney, Toson, Burns, and Dolan (2011) found that while OMT in prison was not
associated with reduced re-incarceration rates, continuation of treatment upon release decreased
re-incarceration by 20%. Opioid maintenance treatment during incarceration is not itself
associated with lower re-incarceration rates, but maintenance at community based OMT programs
is, and OMT initiation and maintenance while in prison leads to higher rates of continued
treatment upon release. Barriers to continuation of treatment upon release may confound the
15

benefits of prison OMT once individuals are reintegrated back into the community. Initiation
and/or continuation of OMT in prison and the resources to smoothly transition from prison OMT
to community OMT upon release benefits both the individuals and the greater community by
reducing rates of re-incarceration.
Magura et al. (2009) compared the outcomes of methadone initiation in the prison setting
to those of buprenorphine initiation. One hundred and sixteen adult male inmates at Riker’s
Island with heroin addiction were randomly administered methadone or buprenorphine treatment.
The researchers found that while there was no significant difference (p<0.001) between the two
groups in completion of the study or rates of recidivism/re-incarceration at Riker’s upon release,
48% of the individuals who had been initiated and maintained on buprenorphine vs. 14% of the
individuals who had been initiated and maintained on methadone continued treatment at an OMT
community clinic upon release. The researchers believed that this vast difference might have been
due to the relative flexibility of community based buprenorphine administration compared to
regionalized methadone centers. This study excluded individuals who had been previously
maintained on methadone at the time of incarceration. This is relevant because individuals who
had been enrolled in methadone treatment before incarceration and were maintained while
incarcerated may have continued treatment at a community clinic after release at a higher rate
than those initiated in prison like the individuals in this study. In addition, the median dosage of
methadone (30mg) administered in this study is considered suboptimal for most patients, while
the median buprenorphine dose (12mg) is considered within the range of optimal for most
patients (Magura et al., 2009). This may have contributed to the lower rates of continuation of
treatment for those in the methadone group, as suboptimal OMT dosing is associated with less
successful treatment (Magura et al., 2009). These results suggest that both ease of accessibility to
treatment and proper dosages may contribute to continuation of treatment upon release, and that
the success of OMT may be related to what type of medication is administered.
16

Health Outcomes and Risk of Overdose Following Release from Prison
Re-incarceration is not the only risk for individuals following release from prison. Health
problems present another barrier to successful reintegration into the community, particularly
ongoing substance abuse and mental health related issues. Binswanger et al. (2011) interviewed
29 previously incarcerated individuals between the ages of 22-57 regarding medical issues they
faced post-prison release. One of the themes that emerged was difficulty accessing health care,
including mental health and addiction care. Many of the participants expressed the wish that they
had been referred to a health care provider or community health clinic pre-release so that they
could have easily accessed care once they left prison. For some participants, difficulty accessing
care meant a delay in treatment for which they suffered complications such as relapse with
substances and worsening health. The fear of relapse into substance use and potential overdose
were reported, which the participants stated were related to inadequate access to care. These
results suggest that access to care post-release may be improved by referrals to health care
providers and substance abuse treatment centers prior to release from prison.
Binswanger et al. (2012) explored the experiences that formerly incarcerated individuals
reported having with overdose of illicit substances after release from prison. Twenty-nine
individuals 18 or older were recruited from community health and addiction clinics and
interviewed two months after release from prison. Three of the participants reported having
overdosed soon after release from prison, and greater than 50% of the participants reported
knowing someone who had experienced an overdose post-release from prison. One major theme
reported was difficulty accessing substance abuse care post-prison release, combined with
unavoidable exposure to drugs in their environment. The stress of reintegration back into the
community, including finding work, shelter, and healthcare was reportedly so intense that
returning to substance use was a commonly reported coping mechanism. The perceived sudden
lack of structure that many individuals were faced with after living in a highly structured prison
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environment was reported to be another stressor. While many of the participants reported
remaining clean from illicit substances while incarcerated, the combination of life stressors paired
with the high levels of substance use and easy access to substances in their communities made it
very difficult to refrain from using substances post-release from prison. Participants also reported
that staying “clean” while incarcerated led to a decreased tolerance for substances, which they felt
led to an increased risk for overdose. The researchers recommended the use of opioid
maintenance treatment both in prison and immediately following release to potentially decrease
this risk (Binswanger et al. 2012). A potential benefit of OMT may be that it provides better
access to care and greater structure in the every day lives of these individuals (Binswanger et al.,
2012).
Increased risk of death related to overdose following release from prison has been clearly
identified. Merral et al. (2009) conducted a meta-analysis that included six studies that followed
inmates aged 18-35 with substance abuse histories for at least 12 weeks post-incarceration. One
thousand thirty three deaths within the first 12 weeks post-prison release were analyzed.
Individuals were at a three to eight-fold increased risk of death related to drug overdose within
the first two weeks after prison release compared to the next 10 weeks (week two through 12).
Seventy-six percent of deaths taking place within the first two weeks post-release were found to
be drug-related. The authors speculated that the increase in risk of drug overdose was due to a
possible decreased drug tolerance of inmates who were free of illicit drugs or OMT in prison.
Increased implementation of OMT both in prison and upon immediate release could potentially
decrease risk of post-prison release associated opioid overdose.
Andrews and Kinner (2012) conducted a chart review utilizing the Australian National
Coroners Information System to explore causes of death post-prison release. Three hundred and
eighty-eight records were reviewed, 45% of which listed accidental substance overdose as cause
of death. Eighty-two percent of the deaths were caused by an opioid, and individuals who died of
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accidental drug overdose were more likely to have had experienced withdrawal in the six months
preceding the incident. The use of multiple substances at one time was described in 72% of the
deaths, with benzodiazepines and alcohol being common co-substances implicated in opioid
overdoses. Like many other researchers referenced above, Andrews and Kinner (2012)
recommend the use of transitional substance abuse treatment programs as well as pre-release
educational programs focusing on opioid overdose prevention and the dangers of polysubstance
use to decrease the risk of post-prison release opioid overdose.
Despite much research on the effects of prison OMT on inmates and previously
incarcerated individuals with regards to relapse, recidivism, and health outcomes, as well as the
rates of mental illness and distress in the prison population, little is known about the lived
experiences of individuals who are tapered from OMT at the time of incarceration. Quantitative
research dominates this area, and the addition of qualitative data may add some important
perspectives concerning the ways in which previously incarcerated individuals view these
experiences. Studies exploring the lived experiences of this population may also help guide
focused research that may lead to more successful interventions to reduce recidivism, increase
quality of life during incarceration and post-release, and improve opiate abuse recovery outcomes
for individuals in the correctional system.
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Screaming Behind a Door: The Experiences of Individuals Incarcerated Without Opioid
Maintenance Treatment
Background & Purpose: Opioid maintenance therapy (OMT) is an effective method of treating
opioid addiction. Of incarcerated individuals in the U.S., 50-85% have a history of substance
abuse, and >80% of inmates with opioid addiction history do not receive treatment. The purpose
of this study was to explore individuals’ experiences after being tapered from OMT upon
incarceration. Methods: Interpretative phenomenological analysis (IPA) was employed using indepth interviewing of 10 participants. Results: Analysis identified six themes that captured the
essence of the participants’ experiences. Implications & Conclusion: Losing OMT upon
incarceration was described as an extremely stressful experience for many individuals, and may
create issues for both inmates and facility staff. Further research is needed to discover ways in
which to improve addiction treatment in prison.

Keywords: Opioid Maintenance Treatment, Substance Abuse, Mental Health
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Introduction
Substance related offenses are responsible for at least half of federal prison sentences.
Between 50-85% of incarcerated individuals in the U.S. have a history of substance abuse, with
20% of those reporting intravenous (IV) drug use (Nunn, 2009). Between 9-13% of incarcerated
individuals in 2004 reported using heroin on a regular basis pre-incarceration (Mumola &
Karberg, 2006), and between 12%-25% of newly arrested individuals tested positive for opioids
upon urinalysis (National Institute of Justice, 2004). The availability of illicit substances in
prisons has been well documented (United Nations Office on Drugs and Crime, 2010), and
associated needle-sharing behaviors in prison settings greatly increase risk for HIV and hepatitis
C acquisition during incarceration (United Nations Office on Drugs and Crime, 2010). Opioid
maintenance treatment (OMT) with either methadone or buprenorphine is an effective method of
decreasing opioid abuse and promoting increased health in community and prison settings
(National Institute on Drug Abuse, 2012). Additionally, OMT decreases an individual’s
involvement with the criminal justice system, risk of HIV/hepatitis C infection (Gordon, Kinlock,
Schwartz, O’Grady, 2008), and increases quality of life in the community-dwelling population
(Nosyk et al., 2012). While detoxification programs are also utilized for treatment of opioid
dependence, they have been found to be less effective than OMT at reducing illicit behaviors,
substance use, and needle sharing (Nosyk et al., 2012). The World Health Organization (WHO,
2013) has called for OMT to play a major role in substance abuse programs, including those in
prison settings, and the National Institute on Drug Abuse (NIDA, 2012) includes OMT in its
principles for addiction treatment of both the general and inmate population.
Opioid maintenance treatment in the prison setting has been found to result in a decrease
in opioid use as well as decreased drug injecting and needle sharing (NIDA, 2012). While
inmates frequently report accessibility to illicit substances and means to inject drugs in prison,
only 55% of U.S. state and federal prisons provide methadone or buprenorphine, and more than
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half of those prisons only do so for pregnant women or to treat chronic pain rather than addiction
(Nunn 2009). More than 80% of inmates with known addiction histories do not receive treatment
while incarcerated (Chandler, Fletcher & Volkow, 2009). Many incarcerated individuals with a
history of opioid abuse have been enrolled in an OMT program prior to incarceration (Fiscella,
Moore, Engerman, Meldrum, 2004), but subsequent rates of initiation into OMT after release
from prison are low, and the risk of overdose is elevated in the period immediately following
reintegration back into the community (WHO, 2013). Hendrich et al. (2011) found that six
months following release from prison, more than 50% of individuals who were able to receive
OMT in prison continued treatment in the community, while only five percent of individuals who
did not receive OMT while incarcerated enrolled in a community-based OMT program upon
release from prison. Individuals with a history of pre-incarceration heroin addiction typically
relapsed within one month of release from prison if they were not enrolled in an OMT program
(Gordon, Kinlock, Schwartz, O’Grady, 2008). Reasons for relapse can include anxiety and
depression related to “stigma associated with being labeled an ex-offender, the need for housing
and legitimate employment, stresses in reunifying with family, and multiple requirements for
criminal justice supervision,” as well as reintegration into a community where substances are
highly available and accessible (Chandler, Fletcher, & Volkow, 2009, p184).
Rates of successful long term, voluntary tapers from OMT in medically supervised
community-based treatment centers are generally considered poor. Nosyk et al.’s (2012)
population-based, retrospective cohort study found that only 13% of community-dwelling
individuals who attempted a medically supervised, voluntary taper from OMT were considered
successful, meaning they avoided relapse and/or reentry into OMT. Tapers that were longer than
12 weeks were associated with greater success than those shorter than 12 weeks. Calsyn, Malcy,
& Saxon (2006) reported a zero percent success rate following a voluntary, medically supervised
(minimum 120 day duration) methadone taper in a community setting, suggesting that voluntary
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taper of methadone is difficult without the added stressors associated with incarceration. Because
the accessibility of OMT in prison settings is poor, many individuals who are enrolled in an OMT
program are involuntarily tapered from methadone or buprenorphine upon incarceration at a rate
that is much faster than what is generally considered appropriate within a community-based OMT
setting (Fiscella, Moore, Engerman, Meldrum, 2004). Given the stress associated with
incarceration, it is important to explore the experiences of individuals who have undergone
involuntary discontinuation or taper while serving time in prison. The purpose of this study was
to discover, explore, and describe individuals’ experiences of incarceration after being tapered
from OMT upon incarceration. Implicit within the goal is to discover the essence of their
experience during this time and learn about what the experience was like for them.
Methodology
Research Design
Interpretative phenomenological analysis (IPA) (Smith, Flowers, & Larkin 2009) was
used to explore, describe, and interpret the experiences of individuals who were involuntarily
tapered from opioid maintenance treatment upon incarceration.
Sampling and Recruitment
The institutional review board approved this study prior to any study procedures. Current
and former patients at a methadone and buprenorphine outpatient treatment center in northern
New England who had been previously incarcerated were the population of interest in this
qualitative study. Inclusion criteria included a history of incarceration that involved an
involuntary taper from OMT and the ability to remember and verbally share this experience.
Participants were 18 or older and English speaking. Exclusion criteria included inability to
complete interviews and pregnancy, due to vulnerable population status. Purposive sampling and
snowball sampling were utilized. Participants were recruited from the OMT clinic using flyers
advertising the study. Counselors at the clinic were also asked to provide clients with information
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about the study and the principal investigator’s (PI) contact information. All interested
individuals contacted the PI directly. Sampling continued until saturation was reached at
interview 7 with an additional 2-3 participant interviews to ensure that the multifaceted nature of
the phenomena was well captured, and that the data included examples of both “similarity and
difference between participants” (Smith, Flowers & Larkin, 2009, p. 51). There were a total of ten
participants, who reported being incarcerated at 4 different facilities in New England, with the
exception of one participant who had been incarcerated in the Southern US. A $20 gift card to a
grocery store was provided as compensation for participant time and travel.
Study Procedures
Flexible, semi-structured, in-depth interviews were conducted in private rooms at the
treatment center that were safe, private, and convenient for the participants and the PI. Interviews
included questions that explored the experience of being tapered from OMT, serving a prison
sentence without OMT, and reintegration back into the community after release. The first
question the PI asked participants was: “Tell me what happened when you were first arrested and
incarcerated.” Interviews lasted 45-75 minutes, and were conducted solely by the PI. Interviews
were audio recorded and then transcribed verbatim. Throughout the study, the PI performed
reflexive journaling in order to explore personal biases and preconceptions that may have affected
the interviewing process (Polit & Beck, 2011). Journaling was performed after especially
emotional interviews, when the PI was disturbed by the participants’ descriptions of mistreatment
in the prison setting. This practice allowed the PI to remain neutral to avoid bias against facility
staff, as well as remaining open to all individual stories of the participants.
Data Analysis
The interviews were transcribed verbatim and cross-checked, then de-identified. The PI
was mindful to consider both the transcribed text and the context of the interview by analyzing
the words chosen (including slang), the body language, and any emotional displays such as
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laughter, weeping, etc. (Ray, 1994). The PI then identified emergent themes from the initial
notations. The PI then considered all cases at once to discover thematic “patterns” that fully
captured the essence of participants’ experiences (Smith, Flowers & Larkin, 2009, p. 101). To
improve the study’s rigor, one participant was contacted for a member-check. The participant
validated that the themes reflected her experience.
Results
Demographic information, utilizing pseudonyms to identify participants, is presented in
Table 1. Six themes emerged upon analysis of the transcribed interviews: 1) “You’re not getting
your meds” (Traumatic taper experiences), 2) “I was crawling out of my skin” (Difficult
withdrawal), 3) “Suck it up, it’s not that bad” (Suboptimal medical care), 4) “Trapped and
helpless” (Co-occurring mental illness), 5) “More in there than out here” (Access to substances in
the facilities), and 6) “I just went looking on the street” (Relapse upon release).
“You’re not getting your meds”
Most of the participants reported that despite what they had heard about the Department
of Correction’s policy to taper inmates receiving OMT, they did not receive a taper. Some
participants were told immediately upon entering the facility that their OMT would be abruptly
discontinued. Bryce shared: “They knew I was on it when I came in and they said it didn’t matter.
Kick rocks, pretty much.” Other participants shared that they were not immediately told whether
they would be receiving OMT or not. Mason said: “They didn’t give me anything…and nobody
told me nothing. And that’s kind of intense, kind of sucks.” One participant, Sierra, stated that she
had to make a scene in order to find out if she was going to receive OMT. She angrily recalled
this experience: “it took like 3 or 4 nights until I started flipping out…screaming behind a door,
like ‘what the fuck is wrong with you people, get someone who does know what’s going on, you
fucking moron’….you have to get them mad at you, until finally, they’re like ‘she won’t shut up
in there’…finally hours later, one the nurses comes down…she’s saying ‘you’re not going to get
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your meds.’” Participants expressed confusion, anger, and frustration about these policies and
wondered why the process couldn’t have been more clear.
All of the participants but one were vehement in their belief that the experience of either
abruptly losing or being tapered from OMT was an unquestionably negative experience. Zev
shared that the taper experience was not only severely uncomfortable, it also negatively impacted
his recovery upon release: “It makes you angry. You kind of stay angry…because you just don’t
care anymore. You’re just like, ‘fuck it, I don’t care. I just want to be high.’” Lila, a participant
who did receive a taper from OMT, reported mixed feelings about this experience:
You know, I’m caught here. Part of me says maybe it was a good thing because it
kind of made me realize, yeah, I can do this without it. So I mean…maybe it was
a good thing. I don’t know. Part of me says it’s a good thing and part of me says
deal with one thing at a time.
Although no other participants expressed the belief that the taper or discontinuation experience
may have been positive, many others echoed the sentiment that dealing with incarceration and
“detox” at the same time was overwhelming. Sierra wondered how the experience fit in with the
goal of rehabilitation, which she believed was the purpose of prison: “All those girls are just
going through emotional hell and I can’t see how that could in any way—that experience could
help anyone. It’d have to cause more trouble. You know?” In summary, all participants reported
that losing OMT, either with a taper or in the case of abrupt discontinuation, was a stressful
experience. In addition, some reported that the experience negatively impacted their recovery
process after release.
“I was crawling out of my skin”
All participants reported an extremely challenging withdrawal, regardless of whether they
had received a taper or abruptly discontinued OMT. Some participants focused on physical
withdrawal symptoms. Jeremy shuddered while recalling his experience: “Every single day was
just dreadful…like I’d get so hot that I’d sweat…I’d shiver and when I was throwing up I wasn’t
throwing up anything. Just foam. Just big, big things of foam and it was nasty.” However, most
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stated that withdrawal while incarcerated was both physically and emotionally taxing. For Bryce,
memories of the emotional turmoil were more vivid:
I felt like it screwed my head up afterwards for awhile. I didn’t feel clear for a
long time…I felt like I was nursing my mind and my body back to health
slowly…It’s a horrible experience. Its really—emotionally its even harder. I can
take the sickness, but you know you’re in jail and you’ve lost everything again
and you’re—I feel like I’m always like—my body is an open wound
emotionally…Then I just starting thinking about my kids and its just…it’s a
dreary place to be.
A few participants reported that even once the acute withdrawal symptoms faded, they
had difficulty engaging and integrating themselves into day-to-day prison life. Donna described
feeling detached: “I just didn’t feel right. Like I was there but I wasn’t kind of. I was very
spacey…I was seeing and doing everything but I really wasn’t in my body doing it…I was just
extremely out of it for probably five months.” The withdrawal experience in prison was
physically and emotionally challenging for all of the participants, and some reported that after
effects associated with withdrawal took months to wear off.
“Suck it up, it’s not that bad”
Despite how ill the participants were during their withdrawal periods, none reported
receiving comprehensive medical care. While some were given “cocktails” for symptom
management (usually including Pepto-Bismol, clonidine, and an anti-histamine) or “vital checks”
(facility staff checks vital signs such as blood pressure and pulse in order to monitor withdrawal),
others reported feeling ignored by the medical staff. Mason received no medical attention: “The
nurses knew about when I was being tapered down, they didn’t come and check. Nobody came to
check nothing.” Donna stated: “They just sat there and said ‘suck it up, its not that bad.’ The most
they would do was give me juice at times because they thought I was going to pass out and they
wanted to get some sugar in my system.” Bryce discovered that pretending to be an alcoholic
helped him receive treatment for withdrawal: “The medical staff is horrible…their opinion is, you
can’t die from opiate withdrawal, so suffer. All of us learned to say that we were drinking
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heavily—they give you Valium for drinking…I don’t drink but I told them that because it was the
only way.”
A few participants stated that they had been placed in a “medical unit” to withdraw,
which they described as feeling more like solitary confinement or “the hole.” Jeremy stated:
I told them I was going to crash real hard and they said, ‘Well, then, what we
need to do is lock you into an empty room’ and gave me a bucket...They didn’t
do anything for me, wouldn’t give me any medication [to help with withdrawal
symptoms].
These participants reported feeling so lonely and frightened in the medical units that they
pretended to be finished withdrawing so that they could join the general prison population. Angel
said:
I was in medical for 5 days and then…I pretty much lied and said I wasn’t
detoxing anymore…I just didn’t want to be in there. I didn’t want to be in the
hole…I just wanted to be in [general] population.
Some participants reported feeling discriminated against by medical staff for having an
addiction history. Bonnie reported that her symptoms weren’t taken seriously because they were
related to opioid withdrawal:
They didn’t seem to believe me when I said it was a medical issue. They kind of
scoffed at that. And they were like ‘Oh, you’ll be alright.’ And I was like ‘Oh,
yeah, right.’ And boy, I wasn’t alright. And—yeah, it was a bad experience. Just
thinking about it gives me the creeps.
Bryce echoed this sentiment: “The medical staff look at you like you’re a piece of shit…they’re
very judgmental, which I don’t think you should be working in a correctional facility.” Many
participants stated that they did not feel like medical staff were interested in helping them or
improving their health status. Sierra wondered why any nurse would choose to work in the prison
system: “I think that maybe I wouldn’t want to go to school to be a nurse and work there, because
you can’t help anybody. So you’d either have to be mean or not care and need money really bad.”
A lack of perceived comprehensive, compassionate health care in prison was stressed by all of the

29

participants, and some reported feeling as though the health care providers did not care whether
they remained healthy.
“Trapped and helpless”
Many of the participants shared that they struggled with mental illness as well as
addiction issues. Two participants stated that their psychotropic medication was withheld, despite
having a prescribing practitioner in the community. Zev shared that he had been prescribed
multiple medications for depression and anxiety, but it took weeks for his medications to be
confirmed with his prescribing physician. Once his medications were confirmed, the correctional
facility’s physician decided not to prescribe some of the medications he had been getting before
incarceration. He felt that this lapse was detrimental to his mental health:
They’re like ‘Eh, no big deal.’ Like…times when I’ve come down off my regular
antidepressants and stuff like…it’s so bad, it can make me want to kill myself or
super angry and like it’s just terrible that they can do that…the doctor without
talking to you can just decide that he knows better than the doctor you see that
knows you…without actually interviewing or talking to you really. They can just
be like ‘Yeah, I don’t think you need that.’
Donna had a similar experience: “I have bipolar…and they wouldn’t give me any of my
medications. I was on Seroquel. They wouldn’t give me any of that. I was on Klonopin…they
wouldn’t give me anything. None of my prescriptions.”
Other participants reported that appointments with mental health counselors and support
meetings were hard to come by. Donna was the only participant who reported having access to a
case manager to talk to while incarcerated, but she only met with her once because she did not
feel comfortable talking with her. She stated that the case manager ignored her concerns and did
not take her seriously when she tried to report that guards were sexually assaulting inmates:
I told someone…a person that you were allowed to talk to if you were on drugs
and you’d get to see them once a week for half an hour and you’d tell them how
you’re doing and stuff like that…she was just like ‘that doesn’t happen,’ just kind
of like brushed it off her shoulder like it was no big deal.
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Max stated that despite the fact that the majority of the fellow inmates he knew had opioid
problems, there were few substance abuse resources: “There were AA meetings…but never any
real Narcotics Anonymous meetings…95 percent of the people were in there for like theft or
stealing something, selling stolen property, all just to pay for their drugs.” Despite the fact that
many of the participants reported a history of mental illness or episodes of depression and anxiety
triggered by incarceration, none were able to access mental health care while incarcerated.
“More in there than out here”
All of the participants stated that substances and drug paraphernalia were accessible in
prison, although there were varying reports about where the drugs came from. Donna reported
that male guards smuggled substances into the facilities in order to bribe inmates that were known
to have addiction issues to engage in sexual favors:
They would want me to do a sexual favor and then they would give me
whatever…if you’re coming off stuff and it looks like you want something,
they’re going to ask you ‘What do you want?’ and they would bring us anything
that we wanted…whether it was drugs or alcohol or needles to do the drugs with
or weed or cigarettes or tobacco whatever.
The trades were sometimes forced: “There was one girl in there that was very young…all the
guards wanted her. Two guys at once wanted to take her and they did—for drugs. And even if
you said no, sometimes they still did it.” The four other female participants confirmed that they
had either witnessed or participated in similar transactions.
Some male participants reported that they had received substances from guards, although
they stated that the guards were interested in money rather than sex. Jeremy told a story about a
guard who smuggled tobacco into prison for him to sell:
There was this female guard that worked there…I said ‘What are you making for
money here?’ And she said ‘$15 an hour.’ And I said ‘How would you like to
make $500 in an hour?’ And she said ‘Let’s hear it.’
Participants stated that substances were also smuggled in by other inmates, who would then sell
or use them. Selling substances in prison was identified as a lucrative business, as many desperate
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inmates were willing to pay high prices. According to Mason, “[An 8mg pill of buprenorphine] is
at least $100, probably $150…it’s like $20 for one little line…its highway robbery. But because
we’re addicts, we’re going to pay whatever.” Many participants reported that individuals worried
about withdrawal smuggled medication into the facilities when they were incarcerated to treat
their symptoms:
…that’s what most people know now…they know they’re not going to get their
medicine so [they smuggle it in]. You’d be crazy not to take care of yourself…If
I was ever in trouble again, I would bring [drugs] in because I would never go
through that again. It was awful.
So many individuals were reportedly smuggling in substances that it might have been easier for
some individuals to find drugs in prison than in the community: “Sometimes there was more in
there [prison] than out here. It’s like when everybody knows they’re going to jail, they do
whatever they have to do to bring [drugs] in.” Mason reported that substances were so accessible
that some inmates became addicted while serving time: “People would get the habit, there was so
much down there. They were catching habits in jail. Some guys…they’d never even been on the
street to buy [drugs] until they got in there.”
The easy accessibility of substances despite the unavailability of methadone or
buprenorphine for regulated treatment in prison led many of the participants to wonder about the
futility of the tapers:
It’s a really big deal there because everyone wants their medicine. It’s really
stupid because most people—most of the entire [prison] population is going to be
back on the medicine when they get out. Most of them aren’t even in there for
more than a year…I mean, if you’re going to give it to them and then take it
away—what a mess.
Bryce reflected on his belief that the refusal by the facilities to provide addiction treatment is
what led to the frequent drug use that they were trying to avoid:
Its silly…they fight so hard to keep [drugs] out of jails…they should just give
[OMT] to anybody who wants it…I just think it’s comical that they fight so hard
to keep it out when they would solve all their problems if they just prescribed it
as a tool for treatment in jail.
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Every participant reported either using substances while in prison or being aware that substances
were easy to access. Many participants shared that guards smuggled substances into prison, and
all of the female participants had either witnessed or participated in a drug trade that involved
sex.
“I just went looking on the street”
Every participant either reported using smuggled substances while in prison or relapsing
soon after release from prison. Some were able to re-enter treatment programs after release, but
even those participants reported a period of time of waiting to re-start treatment in which they
were using substances on the street. Sierra reported using drugs right after release: “I got
out…and just went looking on the street.” For Donna, memories of her experiences in prison
drove her to use drugs upon release:
It was really bad. I mean, I thought I was going to die, I was doing so many drugs
[after release]. I really thought I was going to die…[the incarceration experience]
was traumatic and I was having nightmares and I couldn’t get them to go away so
I was trying to use [drugs] to make them go away.
Although no participants reported overdosing after release, a few stated that they knew people
who had. Zev stated: “ I’ve heard that a lot of people OD [immediately after release]…[some
people] would just want to kill themselves. Because even though you’re out, its still shit.” Angel
reported a more severe addiction once she was released than before incarceration: “Hell. I got
extremely, extremely heavy into dope. I was doing maybe 20 bags a day.” Illicit opioid use upon
release was reported by all of the participants, and some stated that their use after incarceration
was heavier than their use before. Many participants shared stories of friends or acquaintances
who had overdosed when they were released from prison.
Discussion
The purpose of this study was to explore and describe the experiences of individuals who
had their opioid maintenance treatment tapered or discontinued abruptly upon incarceration. The
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six themes uncovered in the analysis of the interviews reflect the profound isolation from the
outside world during incarceration that participants described, especially with regards to the
reported disconnect between what is considered appropriate mental health/substance abuse
treatment and what is received in prison. The participants shared examples of how the practice of
taper or abrupt discontinuation of OMT in the prison setting may have been quite futile and in
fact created a host of issues for both inmates and Department of Corrections staff.
Participants experienced feelings of isolation when they were incarcerated, both isolation
from the outside world by virtue of being prisoners and from general prison life because of their
addiction. Implicit in many of the participants’ stories was the feeling of not being listened to or
having basic needs met. Participants credited this to both their status as prisoners and as addicts.
The participants’ accounts of their experiences also point to a disconnect between what is
provided in the prison setting and what is regarded as acceptable substance abuse treatment in the
addiction treatment field. These findings echo Cropsey et al.’s (2012) research, which found that
only 17.4% of 431 facilities offered methadone maintenance treatment. This leaves most facilities
without basic substance abuse treatment. While Cropsey et al. found that 72.3% of facilities
reported offering “co-occurring mental and substance use disorders counseling,” none of the
participants in this study reported opportunities for counseling that were offered consistently and
felt safe. A combination of OMT and counseling is generally accepted as standard practice for
treatment of opioid addiction by experts in the substance abuse treatment field, and is
recommended by the National Institute on Drug Abuse (2014).
The participants’ reports of relapse upon release are consistent with the findings of
Binswanger et al. (2012) and highlight one of the dangers that face inmates once they leave
prison. Taken together with the accessibility of substances in prison, the purpose of discontinuing
OMT is questionable. If imprisonment is meant to provide rehabilitation or at least discourage
individuals from engaging in the behavior that led to their arrest, a policy that results in the
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continued use of illicit substances and negatively effects recovery seems futile. The interruptions
in OMT treatment that can occur when patients are incarcerated may lead to increased utilization
of resources related to re-admission and re-induction at OMT clinics in the community upon
release.
These findings could inform changes in practice and policy, as well as further research.
Firstly, the loss of OMT upon incarceration, with either a taper or in the case of abrupt
discontinuation is a stressful experience for many individuals, which may have detrimental
effects on their physical and mental health. In addition, inmates may not feel as though their
health needs are adequately addressed by prison medical staff. The general distrust of the
medical staff described by the participants may lead to a failure to report serious medical
symptoms out of the belief that medical staff will do nothing to help. The unavailability of OMT
may lead to increased smuggling of substances into the prison setting, risky use patterns, and
potential corruption of staff, as is also suggested by Schwitters (2014). The findings of the present
study can be added to the growing body of knowledge that suggests that improvements in the
treatment of substance abuse disorders in the prison setting may lead to improved rehabilitation
while in prison, outcomes upon release, and more appropriate use of health care resources.
Further research in this area, including interviews of prison medical staff, may help illuminate
ways in which to improve substance abuse treatment in facilities.
This study had a few limitations. The sample was racially homogenous, with all ten
participants identifying as white. In addition, because the study’s inclusion criteria required that
participants share their experiences in English, the results may not reflect the experiences of nonEnglish speaking populations. All but one participant were enrolled in an OMT program at the
time of the study, and the experiences of individuals who do not re-enter treatment after release
may differ.
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Conclusion
This study adds valuable qualitative data to the body of knowledge concerning substance
abuse treatment in prison settings. The participants shared that experiences that reflect less than
optimal physical and mental health care, especially with regards to their substance abuse and
mental health issues. These stories should prompt further study to explore the current state of
substance abuse treatment for incarcerated populations. Further research in this area may help
guide efforts to reform policies regarding the substance abuse and mental health care provided in
prison settings.
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Table 1. Participant Demographics
Pseudonym

Gender

Age

Current OMT
Medication

OMT at time of
Incarceration &
daily dose

Donna

F

26

Max

M

31

12mg
Suboxone
8mg Suboxone

Mason

M

44

100mg
Methadone
12mg
Suboxone
70mg
Methadone

Angel

F

32

Jeremy

M

31

128mg
Methadone
100mg
Methadone

80mg
Methadone
75mg
Methadone

Bryce

M

41

Sierra

F

39

135mg
Methadone
8mg Suboxone

Zev

M

36

Bonnie

F

59

Lila

F

36

16mg
Suboxone
8mg
Suboxone
55mg
Methadone
“Blind”
voluntary
taper (does
not know
dose),
Methadone
No current
OMT
medication

37

24mg
Suboxone

Duration of
taper

No taper
No taper
A few days
without
medication,
then 1 week
taper
No taper
5mg
decrease/day
for 30 days
No taper
No taper

12mg
Suboxone
Was
participating in
blinded study,
did not know
dose, Suboxone

No taper

8mg Suboxone

30 day taper

No taper
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